ScieGen Pharmaceuticals employs advanced technologies in its analytical development laboratories to ensure the quality and compliance of its generic pharmaceutical products. The laboratories are equipped with sophisticated instruments such as Ultra-Performance Liquid Chromatography (UPLC), High-Performance Liquid Chromatography (HPLC), Gas Chromatography with Headspace (GC-HS), X-ray Diffraction (XRD), Inductively Coupled Plasma Mass Spectrometry (ICP-MS), and particle size analyzers. These tools enable ScieGen's scientists to develop and validate analytical methods that adhere to regulatory standards set by the International Council for Harmonisation (ICH) and the United States Pharmacopeia (USP), ensuring that all products meet stringent quality requirements.

In addition to their state-of-the-art equipment, ScieGen emphasizes a Quality by Design (QbD) approach in their development processes. This methodology allows their teams to apply systematic tools during both the development and validation phases, fostering a deeper understanding of the analytical methods being developed. By adhering to current Good Manufacturing Practices (cGMP) and focusing on method validation, ScieGen Pharmaceuticals aims to maintain high standards of quality and reliability in their product offerings, ultimately contributing to their mission of providing cost-effective and high-quality generic medicines to patients.

United States

ScieGen Pharmaceuticals Inc. is a fast growing generic pharmaceutical manufacturer located in Hauppauge, NY. 

ScieGen Pharmaceuticals

Company Details